Ruxolitinib
1901
Phase 2 small_molecule completed
Quick answer
Ruxolitinib for Myelofibrosis is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ACTUATE THERAPEUTICS, INC.
- Indication
- Myelofibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed